193 related articles for article (PubMed ID: 23878113)
1. Personalised cancer management: closer, but not here yet.
Piccart M
Ann Oncol; 2013 Aug; 24(8):1951-5. PubMed ID: 23878113
[No Abstract] [Full Text] [Related]
2. [Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
[No Abstract] [Full Text] [Related]
3. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
[TBL] [Abstract][Full Text] [Related]
4. Her2-neu: a target in lung cancer?
Andre F; Le Chevalier T; Soria JC
Ann Oncol; 2004 Jan; 15(1):3-4. PubMed ID: 14679110
[No Abstract] [Full Text] [Related]
5. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Ito Y
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
[No Abstract] [Full Text] [Related]
6. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
7. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
8. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
9. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
Kakiuchi S; Yano S; Sone S
Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
[No Abstract] [Full Text] [Related]
10. [Novel target therapies used in breast cancer management].
Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
[No Abstract] [Full Text] [Related]
11. Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.
de Mello RA; de Vasconcelos A; Ribeiro RA; Pousa I; Afonso N; Pereira D; Rodrigues H
Recent Pat DNA Gene Seq; 2012 Apr; 6(1):56-63. PubMed ID: 22239685
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
13. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Flaherty KT; Brose MS
Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
[TBL] [Abstract][Full Text] [Related]
14. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
Campone M; Frenel JS; André F; Bachelot T; Juin P
Bull Cancer; 2012 Jun; 99(6):665-72. PubMed ID: 22614782
[TBL] [Abstract][Full Text] [Related]
15. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Juergens R; Brahmer J
Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib versus cetuximab in lung cancer: round one.
Minna JD; Peyton MJ; Gazdar AF
J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
[No Abstract] [Full Text] [Related]
17. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
18. [Molecular diagnosis of solid tumors].
Yatabe Y
Nihon Rinsho; 2005 Mar; 63(3):434-40. PubMed ID: 15773342
[TBL] [Abstract][Full Text] [Related]
19. Cancer diagnostics: decision criteria for marker utilization in the clinic.
Taube SE; Jacobson JW; Lively TG
Am J Pharmacogenomics; 2005; 5(6):357-64. PubMed ID: 16336001
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Spector N
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
